UPLC-MS/MS-based plasma cardiovascular disease related biomarker targeted metabonomics quantitative method

Abstract

The invention belongs to the field of biological analysis, and relates to a UPLC-MS / MS-based sensitive and reliable plasma cardiovascular disease related biomarker targeted metabonomics quantitative method. Mass spectrum parameters and a liquid chromatography method are optimized, one-time sample injection within 16 min is achieved, and high-flux, high-sensitivity and high-separation-degree detection is conducted on 20 kinds of biomarkers metabolized in ways of aromatic amino acid catabolism, trimethylamine oxide biosynthesis, histidine metabolism and the like. The method is good in linearity, linear correlation coefficients are all larger than 0.99, the intra-day precision and the inter-day precision are 1.12%-14.12% and 0.30%-13.74% respectively, and the recovery rate and the stability can also meet the analysis requirements of biological samples. The targeted metabonomics method has been proved to have a strong ability to accurately analyze metabolic markers, provides valuable information for large-scale biomarker verification, is a material basis for clarifying potential cardiovascular diseases, and provides powerful support for clinical diagnosis or early warning.

Description

technical field [0001] The invention belongs to the field of biological analysis, and relates to a UPLC-MS / MS-based targeted metabonomics quantification method for plasma cardiovascular disease-related biomarkers. Background technique [0002] Cardiovascular disease (CVD) has become a leading cause of death and a serious public health challenge worldwide. According to the World Health Organization, 17.9 million people died from cardiovascular disease in 2016. Without early prevention and intervention strategies, the prevalence of cardiovascular disease will continue to increase. Atherosclerosis resulting from the deposition and progressive accumulation of oxidized low-density lipoprotein cholesterol (LDL-C) is a major cause of CVD. However, its underlying pathogenesis has not been fully elucidated, which hinders early warning and effective risk assessment of CVD. Exploring the pathophysiological basis of this complex disease is an urgent need for the diagnosis of atherosc...

AI Technical Summary

Problems solved by technology

LC-MS / MS techniques have been used to demonstrate associations between cardiovascular disease and certain metabolites such as valine, isoleucine, and leucine, but no reports validate the accuracy and weight of the methods used. However, the content of these methodologies is undoubtedly crucial to obtaining unquestionable results. In addition, the relevant metabolic markers are not comprehensive, and there is no high-throughput quantitative method that covers all relevant markers.

Images